Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shin Nippon Biomedical Laboratories, Ltd. (2395.T)
Tokyo, JP
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.62% | -14.76% | -19.21% | -28.92% | -18.83% | -24.54% | -6.13% | -45.60% | +58.14% | +61.69% | -44.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+0.3% Q1'26: +11.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-7.3% Q1'26: +33.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+5.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+8.2% Q1'26: +10.7% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+2.9% Q1'26: +4.8% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×6.78× Q1'26: 4.67× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.84B
est: 17.90B (-0.4%)
|
14.75B
est: 14.80B (-0.3%)
|
17.24B
est: 16.65B (+3.6%)
|
16.60B
est: 16.15B (+2.8%)
|
15.66B
est: 16.50B (-5.1%)
|
14.56B
est: 14.50B (+0.4%)
|
15.11B
est: 15.50B (-2.5%)
|
17.75B
est: 17.95B (-1.1%)
|
25.09B
est: 25.08B (+0.0%)
|
26.45B
est: 26.20B (+1.0%)
|
32.41B
est: 32.16B (+0.8%)
|
30.58B
30.46B – 30.70B
-4.9% YoY
|
36.61B
36.00B – 37.23B
+19.7% YoY
|
39.86B
39.19B – 40.53B
+8.9% YoY
|
44.49B
43.75B – 45.24B
+11.6% YoY
|
50.76B
49.91B – 51.61B
+14.1% YoY
|
58.82B
57.83B – 59.80B
+15.9% YoY
|
| EBITDA |
1.28B
est: 6.77B (-81.1%)
|
5.45B
est: 5.60B (-2.7%)
|
1.16B
est: 6.30B (-81.6%)
|
338.82M
est: 6.11B (-94.5%)
|
3.39B
est: 6.24B (-45.7%)
|
4.53B
est: 5.49B (-17.5%)
|
5.55B
est: 5.86B (-5.4%)
|
9.49B
est: 6.79B (+39.7%)
|
9.49B
est: 9.49B (0.0%)
|
8.98B
est: 8.97B (+0.2%)
|
8.83B
est: 11.01B (-19.8%)
|
10.47B
10.43B – 10.51B
-4.9% YoY
|
12.53B
12.32B – 12.74B
+19.7% YoY
|
13.64B
13.42B – 13.87B
+8.9% YoY
|
15.23B
14.97B – 15.49B
+11.6% YoY
|
17.38B
17.08B – 17.67B
+14.1% YoY
|
20.13B
19.80B – 20.47B
+15.9% YoY
|
| EBIT |
-108.67M
est: 5.48B (-102.0%)
|
3.85B
est: 4.53B (-15.0%)
|
-386.58M
est: 5.10B (-107.6%)
|
-1.13B
est: 4.95B (-122.9%)
|
2.03B
est: 5.05B (-59.9%)
|
3.30B
est: 4.44B (-25.8%)
|
4.36B
est: 4.75B (-8.2%)
|
8.31B
est: 5.50B (+51.1%)
|
7.88B
est: 7.68B (+2.6%)
|
7.11B
est: 6.94B (+2.5%)
|
6.22B
est: 8.52B (-27.1%)
|
8.10B
8.07B – 8.13B
-4.9% YoY
|
9.70B
9.54B – 9.86B
+19.7% YoY
|
10.56B
10.38B – 10.74B
+8.9% YoY
|
11.79B
11.59B – 11.99B
+11.6% YoY
|
13.45B
13.22B – 13.67B
+14.1% YoY
|
15.58B
15.32B – 15.84B
+15.9% YoY
|
| Net Income |
-1.39B
est: -995.00M (-39.3%)
|
2.65B
est: 2.51B (+5.4%)
|
-915.94M
est: -2.85B (+67.8%)
|
-3.56B
est: -1.97B (-80.6%)
|
1.95B
est: -520.40M (+474.8%)
|
2.55B
est: 2.10B (+21.5%)
|
3.66B
est: 2.10B (+74.5%)
|
7.13B
est: 5.81B (+22.7%)
|
6.06B
est: 5.36B (+13.1%)
|
5.53B
est: 4.28B (+29.2%)
|
4.92B
est: 4.50B (+9.5%)
|
3.48B
3.36B – 3.60B
-22.6% YoY
|
5.01B
4.42B – 5.60B
+44.0% YoY
|
5.54B
4.68B – 6.40B
+10.5% YoY
|
8.80B
8.61B – 8.99B
+58.9% YoY
|
11.00B
10.76B – 11.24B
+25.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
1.07B
est: 5.39B (-80.1%)
|
1.15B
est: 4.46B (-74.3%)
|
1.02B
est: 5.01B (-79.7%)
|
906.25M
est: 4.86B (-81.4%)
|
953.43M
est: 4.97B (-80.8%)
|
859.32M
est: 4.37B (-80.3%)
|
4.48B
est: 4.67B (-4.0%)
|
4.91B
est: 5.40B (-9.2%)
|
6.89B
est: 7.55B (-8.7%)
|
8.12B
est: 8.07B (+0.6%)
|
11.37B
est: 9.91B (+14.8%)
|
9.42B
9.38B – 9.46B
-4.9% YoY
|
11.28B
11.09B – 11.47B
+19.7% YoY
|
12.28B
12.07B – 12.48B
+8.9% YoY
|
13.70B
13.47B – 13.93B
+11.6% YoY
|
15.64B
15.37B – 15.90B
+14.1% YoY
|
18.12B
17.81B – 18.42B
+15.9% YoY
|
| EPS |
-34.84
est: -23.90 (-45.8%)
|
66.52
est: 60.30 (+10.3%)
|
-22.18
est: -68.40 (+67.6%)
|
-85.41
est: -47.30 (-80.6%)
|
46.85
est: -12.50 (+474.8%)
|
61.26
est: 50.40 (+21.5%)
|
87.96
est: 50.40 (+74.5%)
|
171.21
est: 139.55 (+22.7%)
|
145.57
est: 128.71 (+13.1%)
|
132.86
est: 102.81 (+29.2%)
|
118.30
est: 108.00 (+9.5%)
|
83.60
80.70 – 86.50
-22.6% YoY
|
120.35
106.20 – 134.50
+44.0% YoY
|
133.00
112.30 – 153.70
+10.5% YoY
|
211.40
206.79 – 216.01
+58.9% YoY
|
264.20
258.44 – 269.96
+25.0% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ryoichi Nagata | President, Chairman, Chief Executive Officer, Group Chief Financial Officer, Fisheries Business Officer & Chief Health Officer | 144M | — |
| Hideshi Tsusaki | Senior MD, President of Non-Clinical & Global Business Development and Director | — | — |
| Ken Takanashi | Executive Vice President of Group Corporate Management & Global Business & Director | — | male |
| Kyomi Nagatoshi | Senior Managing Executive Officer, Head of General Affairs & Human Resources and Director | — | — |
| Satoshi Matsumoto | Managing Executive Officer & GM of Fisheries Division | — | — |
| Shinji Nitanda | Senior MD of Corporate Development & Corporate Tax Administration and Director | — | — |
| Shu-Ichi Kanazashi | Managing Executive Officer, CMO and General Manager of TR Business Division | — | — |
| Terumasa Hirai | Managing Executive Officer & President and Representative Director of SNBL Ina Research Center | — | — |
| Fumihiko Makino | Senior Executive Officer, Financial Controller and GM of Finance & Accounting | — | — |
| Toshiyuki Iwata | Managing Executive Officer, R/PR Division Manager & Sustainability Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2395.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
